Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + ID-RFA in Extra- and Intrahepatic Cholangiocarcinoma
NCT06440993Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in cholangiocarcinoma (CCA), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall Survival Rate at 12 months. Started Aug 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06440993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440993.